Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (May 2021)
16 slides from Anixa Biosciences's investor presentation, May 27, 2021
Slide 1: Anixa Biosciences
Aanixa BIOSCIENCES May 2021 NASDAQ:ANIX Amit Kumar, PhD Chairman and CEO ak@anixa.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Corporate Background
Corporate Background General & Financial © NASDAQ: ANIX © Bay Area, CA Biotech ¢ Four high value programs Key Collaborators Aanixa £’} Cleveland Clinic dO] THE Strategy: Low Cost Business Model ¢ Invent/in-license technology platforms ¢ Develop technology with partners e Leverage existing infrastruc
Slide 4: Our High Value Programs
our High Value Programs Breast Cancer Vaccine * — Immunize against a-Lactalbumin to prevent Triple Negative Breast Cancer (TNBC) and other breast cancers * Worldwide license * Cleveland Clinic collaboration for IND and clinical trial * $6.2 MM DOD grant will fund pre-clinical work and two Ph 1 clini
Slide 5: Breast Cancer Vaccine - Retired Tissue Specific Protein
Breast Cancer Vaccine- Retired Tissue Specific Protein Inventor and PI: Vincent K. Tuohy, Ph.D. Mort and Iris November Distinguished Chair in Innovative Cancer Research, Cleveland Clinic Retired Tissue Specific Protein a-LACTALBUMIN * Expressed at periods of life, but no longer expressed as we age E
Slide 6: Vaccination Prevents Breast Cancer
Vaccination Prevents Breast Cancer 100 “<= 80 = ® 60 iN a Ss 40 = = - 20 * Vaccinated a 100% of a-LACTALBUMIN vaccinated mice did not develop breast cancer Vaccinated mice did not exhibit autoimmune damage, while single T-cell infiltrates were seen in non-lactating breast tissue (arrows) Aanixa EFFE
Slide 7: Breast Cancer Vaccine Clinical Trial Plan
Breast Cancer Vaccine Clinical Trial Plan Funded by Department of Defense (DOD) Grant $6.2 MM Phase 1b Trial * Healthy women with BRCA1 Phase 1a Trial a mutations Pre-Clinical Studies * TNBC patients who have undergone standard of care * Decided to undergo prophylactic mastectomy ° GLP Tox * IND Fil
Slide 8: Summary: Breast Cancer Vaccine
Summary: Breast Cancer Vaccine KEY ATTRIBUTES MARKET OPPORTUNITY (Estimates) Prophylactic (preventative) vaccines are administered to all eligible, not the small number of sick patients “* — Cleveland Clinic collaboration Expect reimbursement for this vaccine to be similar to VY DOD funded program;
Slide 9: Ovarian Cancer Vaccine - Retired Tissue Specific Protein
Ovarian Cancer Vaccine- Retired Tissue Specific Protein Inventor and PI: Vincent K. Tuohy, Ph.D. Mort and Iris November Distinguished Chair in Innovative Cancer Research, Cleveland Clinic Retired Tissue Specific Protein * Expressed at periods of life, but no longer expressed as we age The Extracellu
Slide 10: CAR-T Technology: Background & Opportunity
CAR-T Technology: Background & Opportunity CAR- Technology has made great inroads in B-Cell cancers * Durable responses (50-80% of patients) * Multibillion dollar valuations and big pharma deals > Novartis - First approved product by FDA > Kymriah for ALL- Acute Lymphoblastic Leukemia 2 Second appro
Slide 11: Anixa's Unique CER-T Approach for Solid Tumors
Anixa’s Unique CER-T Approach for Solid Tumors Novartis, JUNO, KITE and others Anixa’s CAR-T Program for Ovarian Cancer working on B-Cell cancers FSHR- Follicle Stimulating Hormone Receptor Chimeric Endocrine Receptor T-Cell Cancerous Ovarian B-cell CD19 protein Cell FSHR protein (antigen) “Antigen”
Slide 12: FSHR ONLY Expressed in Ovaries and Testes
FSHR ONLY Expressed in Ovaries and Testes *In Healthy Humans* § 0.0025) a g 0.002 ; ey 0.0015 al a ¢ FSHR expressed on the blood vessels $* Ky of many TUMORS in \ = 0.001- \ — . — a \ This therapy will be anti-angiogenic B 0.0005- \ for many types of cancer, enabling a g “ # portfolio of therapies f
Slide 13: Our Magic Bullet
Our Magic Bullet Many tumors have blood vessels where FSHR is expressed even though healthy tissue does not show such expression o Physiologically, FSHR must be helpful in enabling tumors to create vasculature o Outside of the tumor margin, FSHR on blood vessels disappears * Our FSHR targeted CAR-T
Slide 14: Summary: CAR-T Program
Summary: CAR-T Program * Exclusive worldwide license from The Wistar Institute o Tested human CAR-T in immunocompromised mice against human ovarian cancer o Tested murine CAR-T in immunocompetent mice against murine ovarian cancer o Tested human CAR-T in immunocompromised mice against human breast c
Slide 15: Covid-19 Program
Covid-19 Program Initiated April 20, 2020 with partner MolGenie, GmbH — Virtual Screening (1.2 BB compounds) — Targets: Main Protease (M°), Endoribonuclease (NSP-15) ¢ In Silico Hits — Utilize Molecular Modeling, Screening algorithms — “Hits” will be synthesized and tested in vitro - Candidate Drugs
Slide 16: Anixa's Value-Creating Near-Term Milestones
Anixa’s Value-Creating Near-Term Milestones Breast Cancer Vaccine Ovarian Cancer Vaccine ¢ Initiation of Clinical Trial- mid-year 2021 * R&D Data release and publications * Clinical Data Release * Initiate-IND enabling studies Seeking Government funding and alliances CAR-T Program File IND Applicati